183 related articles for article (PubMed ID: 31621441)
21. Healthcare resource use and cost associated with varying dosages of extended corticosteroid exposure in a US population.
Rice JB; White AG; Johnson M; Wagh A; Qin Y; Bartels-Peculis L; Ciepielewska G; Nelson WW
J Med Econ; 2018 Sep; 21(9):846-852. PubMed ID: 29741439
[TBL] [Abstract][Full Text] [Related]
22. The prevalence and disease burden of severe eosinophilic asthma in Japan.
Nagasaki T; Sato K; Kume N; Oguma T; Sunadome H; Ito I; Izuhara Y; Okamoto K; Kobayashi S; Ohno T; Mizukami A; Kobayashi A; Kaise T; Kuroda T; Mishima M; Matsumoto H
J Asthma; 2019 Nov; 56(11):1147-1158. PubMed ID: 30822174
[No Abstract] [Full Text] [Related]
23. Resource utilization in asthma: combined fluticasone propionate/salmeterol compared with inhaled corticosteroids.
Friedman HS; Yawn BP
Curr Med Res Opin; 2007 Feb; 23(2):427-34. PubMed ID: 17288696
[TBL] [Abstract][Full Text] [Related]
24. Economic evaluation and budgetary burden of mepolizumab in severe refractory eosinophilic asthma.
García-Mochón L; Gil-Sierra MD; Alegre-Del Rey EJ; Alarcón de la Lastra-Romero C; Sánchez-Hidalgo M
Farm Hosp; 2019 Nov; 43(6):187-193. PubMed ID: 31705642
[TBL] [Abstract][Full Text] [Related]
25. Respira project: Humanistic and economic burden of asthma in Brazil.
Cançado JED; Penha M; Gupta S; Li VW; Julian GS; Moreira ES
J Asthma; 2019 Mar; 56(3):244-251. PubMed ID: 29595345
[TBL] [Abstract][Full Text] [Related]
26. FourFold Asthma Study (FAST): a study protocol for a randomised controlled trial evaluating the clinical cost-effectiveness of temporarily quadrupling the dose of inhaled steroid to prevent asthma exacerbations.
Skeggs A; McKeever T; Duley L; Mitchell E; Bradshaw L; Mortimer K; Walker S; Parrott S; Wilson A; Pavord I; Brightling C; Thomas M; Price D; Devereux G; Higgins B; Harrison T; Haydock R
Trials; 2016 Oct; 17(1):499. PubMed ID: 27737713
[TBL] [Abstract][Full Text] [Related]
27. Characterizing the severe asthma population in the United States: claims-based analysis of three treatment cohorts in the year prior to treatment escalation.
Sullivan PW; Campbell JD; Ghushchyan VH; Globe G; Lange J; Woolley JM
J Asthma; 2015 Sep; 52(7):669-80. PubMed ID: 25731600
[TBL] [Abstract][Full Text] [Related]
28. A national estimate of the economic costs of asthma.
Smith DH; Malone DC; Lawson KA; Okamoto LJ; Battista C; Saunders WB
Am J Respir Crit Care Med; 1997 Sep; 156(3 Pt 1):787-93. PubMed ID: 9309994
[TBL] [Abstract][Full Text] [Related]
29. An international observational prospective study to determine the cost of asthma exacerbations (COAX).
Lane S; Molina J; Plusa T
Respir Med; 2006 Mar; 100(3):434-50. PubMed ID: 16099149
[TBL] [Abstract][Full Text] [Related]
30. [Use of resources and costs associated with non-adherence to inhaled corticosteroid treatment in asthma].
Sicras-Mainar A; Huerta A; Sánchez D; Navarro-Artieda R
Semergen; 2018; 44(1):13-22. PubMed ID: 28456499
[TBL] [Abstract][Full Text] [Related]
31. A comparison of budesonide/formoterol maintenance and reliever therapy versus conventional best practice in asthma management in Spain.
Quirce S; Barcina C; Plaza V; Calvo E; Muñoz M; Ampudia R; Capel M
J Asthma; 2011 Oct; 48(8):839-47. PubMed ID: 21942354
[TBL] [Abstract][Full Text] [Related]
32. [Socioeconomic Costs of Asthma in the European Union, United States and Canada: A Systematic Review].
Puig-Junoy J; Pascual-Argenté N
Rev Esp Salud Publica; 2017 Mar; 91():. PubMed ID: 28278149
[TBL] [Abstract][Full Text] [Related]
33. Impact of exacerbations on lung function, resource utilization, and productivity: results from an observational, prospective study in adults with uncontrolled asthma.
Wisnivesky J; Federmann E; Eckert L; West E; Amand C; Kamar D; Teper A; Khan AH
J Asthma; 2023 Jun; 60(6):1072-1079. PubMed ID: 36218309
[No Abstract] [Full Text] [Related]
34. Impact of omalizumab on treatment of severe allergic asthma in UK clinical practice: a UK multicentre observational study (the APEX II study).
Niven RM; Saralaya D; Chaudhuri R; Masoli M; Clifton I; Mansur AH; Hacking V; McLain-Smith S; Menzies-Gow A
BMJ Open; 2016 Aug; 6(8):e011857. PubMed ID: 27507234
[TBL] [Abstract][Full Text] [Related]
35. Impact of Mepolizumab on Exacerbations in the US Medicare Population.
Sethi S; Bogart M; Corbridge T; Cyhaniuk A; Hahn B
J Allergy Clin Immunol Pract; 2023 Feb; 11(2):546-554.e2. PubMed ID: 36377070
[TBL] [Abstract][Full Text] [Related]
36. Impact of mepolizumab on exacerbations in severe asthma: Results from a U.S. insurance claims data base.
Ortega H; Hahn B; Bogart M; Bell CF; Bancroft T; Chastek B; Llanos JP
Allergy Asthma Proc; 2020 Sep; 41(5):341-347. PubMed ID: 32867888
[No Abstract] [Full Text] [Related]
37. Disease Burden of Mild Asthma: Findings from a Cross-Sectional Real-World Survey.
Ding B; Small M
Adv Ther; 2017 May; 34(5):1109-1127. PubMed ID: 28391549
[TBL] [Abstract][Full Text] [Related]
38. Exacerbations and healthcare resource utilization among COPD patients in a Swedish registry-based nation-wide study.
Johansson G; Mushnikov V; Bäckström T; Engström A; Khalid JM; Wall J; Hoti F
BMC Pulm Med; 2018 Jan; 18(1):17. PubMed ID: 29370846
[TBL] [Abstract][Full Text] [Related]
39. Clinical and economic effects of suboptimally controlled asthma.
Bootman JL; Crown WH; Luskin AT
Manag Care Interface; 2004 Jan; 17(1):31-6. PubMed ID: 15035598
[TBL] [Abstract][Full Text] [Related]
40. The association between asthma control, health care costs, and quality of life in France and Spain.
Doz M; Chouaid C; Com-Ruelle L; Calvo E; Brosa M; Robert J; Decuypère L; Pribil C; Huerta A; Detournay B
BMC Pulm Med; 2013 Mar; 13():15. PubMed ID: 23517484
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
